03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Indivan* : | |
Type | Medicine Non Marketed |
Originator | Crixivan 400mg* |
Agent | Droguerie de l'Union |
Distributor | Droguerie de l'Union |
Laboratory | Cipla |
Responsible Party | Cipla Ltd |
Origin | India |
Manufacturer | Cipla Ltd |
Manufacturing Type | G |
Origin | India |
ATC | J05AE02 |
Indivan* :
Indivan* :
Indivan* :
Indivan* :
Indivan* :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Abdominal pain | Very Common |
Acute kidney injury | Not known |
Alopecia | Not known |
ALT increased | Very Common |
Anaemia | Not known |
Anaphylactoid reactions | Not known |
AST increased | Very Common |
Asthenia | Very Common |
Autoimmune disorder | Not known |
Basedow's disease | Not known |
Blood alkaline phosphatase increased | Not known |
Blood creatine phosphokinase increased | Not known |
Blood creatinine increased | Not known |
Body fat disorder | Not known |
Crystalluria | Very Common |
Diabetes mellitus | Not known |
Diarrhoea (Diarrhea) | Very Common |
Dizziness | Very Common |
Dry mouth (Xerostomia) | Common |
Dry skin | Very Common |
Dysguesia (taste perversion) (Taste abnormality) (Taste disturbance) | Very Common |
Dyspepsia | Very Common |
Dysuria (Micturition painful) | Common |
Erythema multiforme | Not known |
Fatigue | Very Common |
Flank pain | Not known |
Flatulence | Common |
Haematuria (Hematuria) | Very Common |
Haemolytic anemia | Not known |
Haemorrhagic diathesis | Not known |
Headache | Very Common |
Hepatic failure (Hepatic insufficiency) (Liver failure) | Not known |
Hepatic function abnormal | Not known |
Hepatitis | Not known |
Hyperbilirubinaemia | Very Common |
Hypercholesterolaemia | Not known |
Hyperglycaemia | Not known |
Hyperlactacidaemia | Not known |
Hypersensitivity vasculitis | Not known |
Hypertriglyceridaemia | Not known |
Hypoesthesia | Common |
Immune reconstitution inflammatory syndrome | Not known |
Ingrowing nail | Not known |
Insomnia | Common |
Insulin resistance | Not known |
Leukocytosis | Not known |
Lipoatrophy | Not known |
Lipomatosis | Not known |
Mean cell volume increased | Very Common |
Metabolic disorder | Not known |
Myalgia | Common |
Myositis | Not known |
Nausea | Very Common |
Nephrolithiasis | Common |
Neutrophil count decreased | Very Common |
Osteonecrosis | Not known |
Pancreatitis | Not known |
Paraesthesia (paresthesia) | Common |
Paraesthesia oral | Not known |
Paronychia | Not known |
Periarthritis | Not known |
Product deposit | Not known |
Proteinuria | Very Common |
Pruritus | Common |
Pyelonephritis | Not known |
Pyrexia | Not known |
Regurgitation | Common |
Renal failure | Not known |
Rhabdomyolysis | Not known |
Skin hyperpigmentation | Not known |
Skin rash | Very Common |
Stevens-Johnson syndrome | Not known |
Thrombocytopenia (Thrombopenia) | Not known |
Tubulointerstitial nephritis | Not known |
Urticaria | Not known |
Vomiting | Very Common |
NB : Products With Same Indication |
Different Units By MoH Code
Indivan* MoH 2467 :
Form | Capsule, hard |
Package Size | Box of 60 |
Strength | 400mg |
NSSF | ✘ |
Quarantine | ✘ |
Reg. Number | 208581/03 |
Submission date | 01/01/2003 |
Registration Year | 2003 |
Archived Date | 2017 |
Price Comparison
You have to register to view this info
Drop File